Tocilizumab monotherapy in a patient with rheumatoid arthritis and iatrogenic Kaposi sarcoma

Clinical Drug Investigation

Volumn 34, Issue 2, 2014, Pages 159-161

  Ingegnoli, Francesca ^a   Tourlaki, Athanasia ^b   Gualtierotti, Roberta ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; GOLD SALT; HYDROXYCHLOROQUINE; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; METHOTREXATE; PREDNISONE; RHEUMATOID FACTOR; SALAZOSULFAPYRIDINE; TOCILIZUMAB;

ADULT; ARTICLE; CASE REPORT; DISEASE ACTIVITY SCORE; DRUG SAFETY; DRUG WITHDRAWAL; HUMAN; HUMAN HERPESVIRUS 8; HUMAN TISSUE; IATROGENIC DISEASE; KAPOSI SARCOMA; MALE; MONOTHERAPY; POLYARTHRITIS; PRIORITY JOURNAL; PROTEINURIA; RASH; RELAPSE; REMISSION; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SKIN BIOPSY; SKIN DEFECT;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ARTHRITIS, RHEUMATOID; HUMANS; IATROGENIC DISEASE; MALE; RECEPTORS, INTERLEUKIN-6; REMISSION INDUCTION; SARCOMA, KAPOSI; TREATMENT OUTCOME;

EID: 84898938011     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.1007/s40261-013-0159-9     Document Type: Article

References (17)

1. Genovese MC, McKay JD, Nasonov EL, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum. 2008;58(10):2968-80.
2. Dougados M, Kissel K, Sheeran T, et al. Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY). Ann Rheum Dis. 2013;72(1):43-50.
3. Alten R, Maleitzke T. Tocilizumab: a novel humanized anti-interleukin 6 (IL-6) receptor antibody for the treatment of patients with non-RA systemic, inflammatory rheumatic diseases. Ann Med. 2013;45(4):357-63.
4. Antman K, Chang Y. Kaposi's sarcoma. N Engl J Med. 2000;342(14):1027-38. (Pubitemid 30180651)
5. Mezalek ZT, Harmouche H, Attar NE, et al. Kaposi's sarcoma in association with Behcet's disease: case report and literature review. Semin Arthritis Rheum. 2007;36(5):328-31. (Pubitemid 46533853)
6. Martínez-Martínez ML, Pérez-García LJ, Escario-Travesedo E, et al. Kaposi sarcoma associated with infliximab treatment. Actas Dermosifiliogr. 2010;101(5):462-4.
7. Ursini F, Naty S, Mazzei V, et al. Kaposi's sarcoma in a psoriatic arthritis patient treated with infliximab. Int Immunopharmacol. 2010;10(7):827-8.
8. Cohen CD, Horster S, Sander CA, et al. Kaposi's sarcoma associated with tumour necrosis factor alpha neutralising therapy. Ann Rheum Dis. 2003;62(7):684. (Pubitemid 36760574)
9. Law AB, Ryan G, Lade S, et al. Development of Kaposi's sarcoma after complete remission of multicentric Castlemans disease with rituximab therapy in a HHV8-positive, HIV-negative patient. Int J Hematol. 2010;91(2):347-8.
10. Nicoli P, Familiari U, Bosa M, et al. HHV8-positive, HIV-negative multicentric Castleman's disease: early and sustained complete remission with rituximab therapy without reactivation of Kaposi sarcoma. Int J Hematol. 2009;90(3):392-6.
11. Terasaki Y, Okumura H, Saito K, et al. HHV-8/KSHV-negative and CD20-positive primary effusion lymphoma successfully treated by pleural drainage followed by chemotherapy containing rituximab. Intern Med. 2008;47(24):2175-8.
12. Pantanowitz L, Früh K, Marconi S, et al. Pathology of rituximab-induced Kaposi sarcoma flare. BMC Clin Pathol. 2008;23(8):7.
13. Nishimoto N, Terao K, Mima T, et al. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood. 2008;112(10):3959-64.
14. Suthaus J, Stuhlmann-Laeisz C, Tompkins VS, et al. HHV-8-encoded viral IL-6 collaborates with mouse IL-6 in the development of multicentric Castleman disease in mice. Blood. 2012;119(22):5173-81.
15. Morris VA, Punjabi AS, Wells RC, et al. The KSHV viral IL-6 homolog is sufficient to induce blood to lymphatic endothelial cell differentiation. Virology. 2012;428(2):112-20.
16. An J, Lichtenstein AK, Brent G, et al. The Kaposi sarcoma-associated herpesvirus (KSHV) induces cellular interleukin 6 expression: role of the KSHV latency-associated nuclear antigen and the AP1 response element. Blood. 2002;99(2):649-54. (Pubitemid 34533104)
17. Beck JT, Hsu SM, Wijdenes J, et al. Alleviation of systemic manifestations of Castleman's disease by monoclonal anti-interleukin-6 antibody. N Engl J Med. 1994;330(9):602-5. (Pubitemid 24065794)